CSBR
Champions Oncology Inc
$
6.970
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.970
Open
6.970
VWAP
6.97
Vol
519.00
Mkt Cap
96.03M
Low
6.970
Amount
3.62K
EV/EBITDA(TTM)
13.33
Total Shares
13.59M
EV
86.46M
EV/OCF(TTM)
11.71
P/S(TTM)
1.72
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
13.51M
-3.9%
-0.010
-109.09%
14.04M
+4.1%
0.010
-80%
16.56M
-2.8%
0.100
-69.7%
Estimates Revision
The market is revising No Change the revenue expectations for Champions Oncology, Inc. (CSBR) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 17.74%.
Revenue Estimates for FY2026
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2026
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+17.74%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast CSBR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSBR is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.970
Low
12.00
Averages
12.00
High
12.00
Current: 6.970
Low
12.00
Averages
12.00
High
12.00
Craig-Hallum
Matt Hewitt
Strong Buy
Maintains
$8 → $12
2025-03-12
Reason
Craig-Hallum
Matt Hewitt
Price Target
$8 → $12
2025-03-12
Maintains
Strong Buy
Reason
Craig-Hallum analyst Matt Hewitt raised the firm's price target on Champions Oncology to $12 from $8 and keeps a Buy rating on the shares. The firm notes the company reported strong Q3 results, which featured a substantial data licensing deal signed by a large pharma company for rights to their cancer data. The company recognized $4.5M for this with potential of up to $8M. This deal led to revenues of $17M vs. $12.9M estimates and led to beats across the board. Craig-Hallum sees this company capitalizing on its large data offerings as it seeks to make drug development more efficient for customers.
Craig-Hallum
Matt Hewitt
Strong Buy
Maintains
$6 → $8
2024-12-12
Reason
Craig-Hallum
Matt Hewitt
Price Target
$6 → $8
2024-12-12
Maintains
Strong Buy
Reason
Craig-Hallum
Matt Hewitt
Hold
to
Strong Buy
Upgrades
$6
2024-09-12
Reason
Craig-Hallum
Matt Hewitt
Price Target
$6
2024-09-12
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Champions Oncology Inc (CSBR.O) is 29.64, compared to its 5-year average forward P/E of 44.58. For a more detailed relative valuation and DCF analysis to assess Champions Oncology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
44.58
Current PE
29.64
Overvalued PE
96.17
Undervalued PE
-7.02
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
21.94
Current EV/EBITDA
28.02
Overvalued EV/EBITDA
72.00
Undervalued EV/EBITDA
-28.12
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
1.94
Current PS
1.47
Overvalued PS
2.69
Undervalued PS
1.19
Financials
Annual
Quarterly
FY2025Q4
YoY :
-11.76%
12.36M
Total Revenue
FY2025Q4
YoY :
-1145.12%
-1.71M
Operating Profit
FY2025Q4
YoY :
+1583.49%
-1.84M
Net Income after Tax
FY2025Q4
YoY :
+1200.00%
-0.13
EPS - Diluted
FY2025Q4
YoY :
-464.26%
6.62M
Free Cash Flow
FY2025Q4
YoY :
-14.66%
41.15
Gross Profit Margin - %
FY2025Q4
12.29
FCF Margin - %
FY2025Q4
YoY :
+1803.85%
-14.85
Net Margin - %
FY2025Q4
452.70
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CSBR News & Events
Events Timeline
2025-07-18 (ET)
2025-07-18
08:33:03
Champions Oncology appoints Rob Brainin as CEO
2025-07-08 (ET)
2025-07-08
08:50:51
Champions Oncology announces launch of radiopharmaceutical services platform
2025-04-28 (ET)
2025-04-28
09:47:24
Champions Oncology obtains radioactive materials license
Sign Up For More Events
Sign Up For More Events
News
2.0
04-13Yahoo FinanceChampions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year
4.0
03-12Business InsiderChampions Oncology price target raised to $12 from $8 at Craig-Hallum
3.0
03-04NASDAQ.COMCHAMPIONS ONCOLOGY Earnings Preview: Recent $CSBR Insider Trading, Hedge Fund Activity, and More
Sign Up For More News
People Also Watch
XNET
Xunlei Ltd
8.135
USD
-7.45%
SEER
Seer Inc
2.050
USD
0.00%
LFT
Lument Finance Trust Inc
2.100
USD
0.00%
LTRX
Lantronix Inc
3.400
USD
-0.87%
CABA
Cabaletta Bio Inc
1.770
USD
0.00%
SBFG
SB Financial Group Inc
20.770
USD
0.00%
CMT
Core Molding Technologies Inc
17.980
USD
+0.45%
NEON
Neonode Inc
23.030
USD
0.00%
OPTT
Ocean Power Technologies Inc
0.517
USD
+2.17%
FAQ
What is Champions Oncology Inc (CSBR) stock price today?
The current price of CSBR is 6.97 USD — it has increased 0 % in the last trading day.
What is Champions Oncology Inc (CSBR)'s business?
What is the price predicton of CSBR Stock?
What is Champions Oncology Inc (CSBR)'s revenue for the last quarter?
What is Champions Oncology Inc (CSBR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Champions Oncology Inc (CSBR)'s fundamentals?
How many employees does Champions Oncology Inc (CSBR). have?